- Home
- CMDB vs PALI Comparison
CMDB vs PALI Comparison
Compare CMDB & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | PALI |
|---|---|---|
| Founded | 2023 | 1996 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 311.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CMDB | PALI |
|---|---|---|
| Price | $15.94 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 39.7K | ★ 6.3M |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $799,159,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 152.53 | N/A |
| 52 Week Low | $8.46 | $0.53 |
| 52 Week High | $17.57 | $2.64 |
Technical Indicators
Market Signals| Indicator | CMDB | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 46.64 |
| Support Level | $14.91 | $1.64 |
| Resistance Level | $15.45 | $1.96 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 85.97 | 39.18 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.